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Abstract
Primate lentiviruses encode four ‘‘accessory proteins’’ including Vif, Vpu, Nef, and Vpr/Vpx. Vif and Vpu counteract the
antiviral effects of cellular restrictions to early and late steps in the viral replication cycle. We present evidence that the Vpx
proteins of HIV-2/SIVSM promote virus infection by antagonizing an antiviral restriction in macrophages. Fusion of
macrophages in which Vpx was essential for virus infection, with COS cells in which Vpx was dispensable for virus infection,
generated heterokaryons that supported infection by wild-type SIV but not Vpx-deleted SIV. The restriction potently
antagonized infection of macrophages by HIV-1, and expression of Vpx in macrophages in trans overcame the restriction to
HIV-1 and SIV infection. Vpx was ubiquitylated and both ubiquitylation and the proteasome regulated the activity of Vpx.
The ability of Vpx to counteract the restriction to HIV-1 and SIV infection was dependent upon the HIV-1 Vpr interacting
protein, damaged DNA binding protein 1 (DDB1), and DDB1 partially substituted for Vpx when fused to Vpr. Our results
indicate that macrophage harbor a potent antiviral restriction and that primate lentiviruses have evolved Vpx to counteract
this restriction.
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Introduction
The genomes of primate and non-primate lentiviruses encode
‘‘accessory’’ proteins from short open reading frames which are
absent from the genomes of simple retroviruses [1]. The function
of two of the accessory proteins, the Vif and Vpu proteins, have
been defined: Vif antagonizes the antiviral activity of cellular
Apobec 3 cytidine deaminases [2] and Vpu antagonizes the
activity of tetherin to promote release of virions from the cell
surface [3]. In all HIV and SIV lineages, the central viral region
(overlapping Vif and Tat open reading frames) encodes at least
one gene which is usually termed viral protein R (Vpr). Members
of the HIV-2/SIVSM/SIVMAC lineage contain an additional gene
in this region termed viral protein X (Vpx) which was originally
derived from the African green monkey vpr gene by an ancestral
recombination event [4]. Both Vpr and Vpx proteins are packaged
into virions through association with the Gag polyprotein [5–7]
and this points to an early role for these proteins in the virus life
cycle (i.e., at a point proceeding de novo production of viral
proteins). Most of the information regarding the roles of Vpr and
Vpx proteins in primate lentivirus replication has been derived
from studies with HIV-1 Vpr. The Vpr protein of HIV-1 has been
shown to promote the accumulation of cells in the G2 stage of the
cell cycle [8–11] and to associate with the DNA repair enzyme
Uracil DNA glycosylase[12]. In addition, Vpr has been shown to
promote the infection of terminally differentiated macrophages
and dendritic cells [13–17]. These HIV-1 Vpr-ascribed activities
segregate between the Vpx and Vpr proteins of HIV-2/SIVSM:
Vpr of HIV-2/SIVSM induces cell cycle arrest and associates with
UDG but is dispensable for macrophage infection while Vpx
neither induces cell cycle arrest nor associates with UDG [4,18].
However, Vpx is essential for infection of simian macrophages by
SIV in vitro and following infection of simian macrophages by
Vpx minus SIVSM, late cDNA product are reduced while 2-LTR
cDNAs, which are formed only after completion of reverse
transcription, are absent [4,18]. Whether any of these activities
relate to the functional role of Vpr/Vpx proteins in primate
lentivirus replication, is unclear. In order to understand the
functions of the Vpr/Vpx proteins in macrophage infection, we
have focused on Vpx because of its profound impact on
macrophage infection. In addition, its effect can be studied
independently of other Vpr/Vpx-assigned activities including
UDG association and cell cycle arrest.
Results
Vpx is required for infection of heterokaryons between
permissive and non-permissive cells
We previously demonstrated that Vpx of HIV-2/SIVSM was
essential for early events in macrophage infection yet dispensable
for infection of CD4 lymphocytes [4]. We studied Vpx function in
the context of SIVSM PB j which represents a primary isolate [19].
To increase particle infectivity and facilitate analysis of early
events in the viral life cycle, viruses were pseudotyped with VSV-G
envelope proteins. Although VSV pseudotyping has been shown to
alleviate the defects exhibited by other accessory gene mutants
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such as Nef, pseudotyping did not alleviate the infectivity defect of
Vpx-deleted viruses in macrophages. In order to gauge infection of
primary macrophages under single cycle conditions, we quanti-
tated viral cDNAs (mainly 2-LTR cDNA) by real time PCR. In
this study, where we were dealing with a restriction and the viral
target of the restriction was unknown, it seemed prudent to
conduct experiments predominantly with viruses intact for all open
reading frames as opposed to recombinant indicator viruses.
The profound requirement for Vpx in macrophage infection by
HIV-2/SIVSM is illustrated in Figure 1A. 2-LTR cDNA is
formed only after completion of viral reverse transcription and
translocation of viral cDNA to the nucleus where circularization
occurs. Levels of 2-LTR cDNA in macrophages infected with a
wild-type SIV and an SIV variant lacking Vpr were indistinguish-
able (Figure 1A). In contrast, viral 2-LTR cDNA was reduced at
least 100 fold in macrophages infected with an SIV variant lacking
Vpx (Figure 1A). In COS cells and in HeLa cells, viral cDNA
synthesis with wild type and Vpr-deleted or Vpx-deleted viruses
were similar. Although 2-LTR cDNA was not detected in
macrophages infected with SIVD Vpx, late viral cDNAs were
evident but at a reduced level. Late cDNAs were reduced 15 fold
and 2 fold at 24 and 48 h respectively in SIVD Vpx as compared
to wild type infection of macrophages (Figure S1). Our original
study [4] on the requirement for Vpx in SIV infection of monkey
macrophages reported a predominant defect in 2-LTR circle
formation and an approximately 3 fold defect in late cDNA
synthesis using non quantitative PCR. This is consistent with the
defect observed in this study which involves infection of human
macrophages with SIV. The greater than 100 fold defect in 2-LTR
cDNA formation was recapitulated in macrophage infections with
Vpx deleted SIV variants expressing GFP (Figure 1A). This
analysis revealed that an SIV variant lacking Vpx was at least 100
fold less infectious than the wild type counterpart (Figure 1A).
Although Vpx was necessary for macrophage infection, it was
dispensable for infection of COS/HeLa cells (Figure 1A). This
suggested the existence of cellular activities, differentially expressed
between macrophages and COS or HeLa cells, which impact
primate lentivirus infection. One possibility was that COS and
HeLa cells contain a cellular activity which promotes virus
infection but in macrophages, this activity must be activated by the
Vpx protein. An alternative possibility was that macrophages
contain a cellular restriction to infection which is counteracted by
the Vpx protein and this cellular restriction is not expressed in
COS or HeLa cells. To distinguish between these two possibilities,
we used a strategy previously adopted to characterize the
mechanism by which Vif promotes viral infection [20,21].
Heterokaryons were generated between macrophages and COS
cells and the susceptibility of the heterokaryons to infection by
SIVWT and SIVD Vpx was compared. When the fusogenic
proteins of Newcastle Disease Virus (NDV) were expressed in
COS cells, these cells readily underwent fusion with primary
macrophages (Figure 1B). Macrophage/COS heterokaryons
(double staining cells) were isolated by fluorescence-activated cell
sorting (FACS). Double staining cells were not observed when
normal COS cells (not expressing NDV proteins) were mixed with
macrophages (Figure 1B). As an additional control, macrophage
homokaryons were produced using polyethylene glycol (PEG).
Both macrophage/COS heterokaryons as well as COS and
macrophage homokaryons were infectible by wild type SIV
(Figure 1B). In contrast, macrophage homokaryons and macro-
phage/COS heterokaryons were resistant to SIVD Vpx infection
(Figure 1B). Since fusion with COS cells did not relieve the block
to macrophage infection by SIVD Vpx, this indicated that
macrophages harbor an antiviral restriction which is counteracted
by the Vpx protein and this restriction is absent from COS and
HeLa cells.
Vpx counters the restriction in trans
Vpx and Vpr are virion proteins and would thus be predicted to
exert their function in the target cell shortly after infection and
prior to de novo synthesis of viral proteins. Therefore, we examined
whether Vpx delivered to macrophages would alleviate the
restriction in trans to subsequent infection by a Vpx deleted virus.
Macrophages were first infected (1u infection) with envelope
deleted SIV variants harboring intact or defective Vpx genes
(Figure 2). After an additional 8 or 16 hours, macrophages were
subsequently super-infected (2u infection) with wild type or D Vpx
SIV variants. Viral cDNA products were amplified using
envelope-specific PCR primers (Figure 2). cDNA products
amplified by these envelope specific primers were derived
specifically from the secondary (2u) infection since viruses used
in the primary infection (1u) lacked an intact envelope gene
(Figure 2). Infection of macrophages harboring a wild type Vpx
gene alleviated the block to subsequent SIVD Vpx super-infection
8 or 16 hours later (Figure 2). In contrast, macrophages initially
infected with a DVpx SIV remained refractory to subsequent
super-infection (Figure 2). Infection of macrophages with SIVWT
also removed the restriction to subsequent infection by a Vpx
minus SIV variant expressing GFP (Figure 2). This provided
evidence that Vpx, delivered to the target cell, can counteract the
restriction in trans.
Role of ubiquitylation in biological activity of Vpx
Primate lentiviruses have evolved the accessory protein Vif to
counteract the antiviral activity of cellular Apobec 3 cytidine
deaminases [22]. Vif achieves this by promoting ubiquitylation
and proteasomal destruction of Apobec 3 proteins [23]. To
evaluate a possible role for the ubiquitin-proteasome system in the
activity of Vpx, we first evaluated whether Vpx itself was
ubiquitylated. HA-tagged Vpx and mutants thereof (Figure 3A,
lower panel) were co-expressed in 293T cells with 6-Histidine-
myc-tagged ubiquitin. Mono and poly ubiquitylated Vpx proteins
were purified on nickel beads and Western blotted. Immunoblot-
ting with an HA antibody revealed the presence of mono and poly
ubiquitylated forms of Vpx (Ub-Vpx, Figure 3A). We also
examined whether Vpx was ubiquinated by endogenous ubiquitin
(as opposed to over expressed and tagged ubiquitin). HA-tagged
Author Summary
Defense against infection by the primate lentiviruses HIV/
SIV is mediated primarily by antibodies that can neutralize
the virus and by cytotoxic cells that can recognize and kill
other virus-infected cells. However, in the past several
years, research has revealed the existence of an additional
line of host defense against HIV/SIV. It is now apparent
that cells contain factors (also known as cellular restric-
tions) that potently inhibit virus infection. This has forced
primate lentiviruses to evolve a strategy to counteract
these cellular restriction factors. For example, HIV/SIV
encode an accessory protein called Vif, whose function is
to neutralize a cellular restriction to HIV/SIV infection. Our
study provides evidence for a novel restriction that is
expressed by macrophages and which potently antago-
nizes HIV and SIV infection. We describe how the virus
protects itself from this cellular restriction. The goal is to
harness this cellular restriction as the basis for a novel
therapeutic strategy against HIV infection.
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Vpx was expressed in 293 T cells and cell lysates were directly
Western blotted and probed with an HA antibody. This revealed
the presence of higher molecular weight ubiquitylated forms of
Vpx (Figure 3A, right panel). The extent of Vpx ubiquityla-
tion was reduced to various extents in Vpx mutants containing
single or multiple lysine to arginine substitutions (Figure 3A).
Despite mutagenesis of all four lysines in Vpx, polyubiquitylated
forms of the protein were still evident (compare GFP signal with
VpxM4 signal). This suggested an involvement of both lysine and
nonlysine residues in Vpx ubiquitylation [24,25]. The ability of
the Vpx lysine mutants to support SIV infection of macrophages
was next examined. The various mutants were packaged within
SIVDVpx virions and single cycle infection of macrophages was
evaluated from synthesis of late viral cDNAs and 2-LTR cDNAs
(Figure 3B). The infectivity of the Vpx lysine mutants was
impaired to various degrees (Figure 3B). The Vpx mutated
lacking all four lysine (VpxM4) exhibited the lowest infectivity for
macrophage. However, a mutant lacking the two N-terminal
lysines (VpxNM2) appeared to be efficiently ubiquitylated yet this
mutant also exhibited a significant infectivity defect (Figure 3B).
However, due to technical obstacles in transfection of primary
macrophages, we were unable to evaluate the extent of Vpx
ubiquitylation of the various lysine mutants in primary macro-
phages and for this reason, we were unable to directly assess
whether the extent of Vpx ubiquitylation was proportional to
Vpx biological activity. For subsequent experiments, we focused
on the use of Vpx mutant (VpxM4) containing substitutions at all
four lysine residues. This mutant was efficiently packaged within
virus particles at levels indistinguishable from wild type Vpx
(Figure 3C). The packaging of the Vpx lysine mutant in viral
particles suggests, at the very least, that this mutant is competent
for binding to the p6 domain of the viral Gag polyprotein
through which packaging of Vpr and Vpx proteins is mediated
[5,6].
Figure 1. Vpx antagonizes an antiviral restriction in macrophages. (A) Differential susceptibility of macrophages and cell lines to infection
by wild type and Vpx-deleted (DVpx) or Vpr-deleted (DVpr) variants of SIVSM. Virus infection was gauged from the levels of viral 2-LTR cDNA at 24 and
48 h post infection. Right panels, comparison of infectivity of wild type and Vpx deleted SIV GFP variants. Macrophages were infected with 107, 106 or
105 RT unites of SIVWT -GFP or 10
7 RT units of SIVDVpx GFP. Macrophages were visualized 48 h post infection by phase and fluorescence microscopy
(B) Differential infectivity of wild type and Vpx-deleted SIV variants for macrophage-COS heterokaryons. Heterokaryons were formed between
primary macrophages and between COS cells expressing fusogenic HN and F proteins of Newcastle Disease Virus. To visualize heterokaryons by
fluorescence microscopy, COS cells were stained with DiO (green) and macrophages were stained with DiI (red) (magnification6320; left panel). FACS
analysis of macrophage-COS heterokaryons (middle panel). COS cells were cotransfected with NDV HN and F expression vectors (COS-NDV) or with
empty, control vectors (COS). COS cells were stained with CellTracker Green CMFDA and macrophages were stained with CellTracker Blue CMAC.
Double-stained cells were sorted as indicated by the gate. Susceptibility of macrophage/COS heterokaryons and COS and macrophage homokaryons
to infection by SIVWT and SIVDvpx virus variants (right panel). Infection was gauged from levels of late cDNAs and 2-LTR circle cDNAs (error bars are s.d.
of 6 replicate samples from two independent experiments).
doi:10.1371/journal.ppat.1000057.g001
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Vpx activity requires a functional proteasome
We next examined whether the ability of Vpx to regulate SIV
infection of macrophages required proteasome function. Macro-
phages were treated with three different proteasome inhibitors and
then infected with wild type SIV and 2-LTR cDNA was
quantitated 24 and 48 hours after infection. Lactacystin had a
Figure 2. Vpx delivered to macrophages by SIVWT infection removes a block to subsequent infection by SIVDvpx. (A) Macrophages
were initially infected (1u infection) with envelope deleted SIV variants harboring intact or defective Vpx genes. The nature of the envelope deletion is
shown in the lower panel. Those cells were then super-infected (2u infection) with SIVWT or SIVDvpx variants harboring intact envelope genes. cDNA
products resulting from the super infection were then specifically amplified using envelope-specific primers. (B) Similar experiment was performed
using SIVWT or SIVDvpx for 1u infection and SIVWT or SIVDvpx GFP variants for 2u infection. Number of GFP-positive cells was determined 24 hr post 2u
infection (error bars are s.d., n = 3).
doi:10.1371/journal.ppat.1000057.g002
Figure 3. Role of the proteasome ubiquitylation system in regulation of SIV infectivity by Vpx. (A) Identification of ubiquitylated
residues in Vpx. Wild type and lysine mutant Vpx proteins (HA tag) were expressed in 293T cells expressing Histidine-tagged ubiquitin. (B)
Susceptibility of primary macrophages to infection by SIVDvpx packaging either wild type Vpx or lysine substitution mutants of Vpx. Vpx proteins were
packaged after co-transfection of SIVDvpx proviral DNA with plasmids expressing wild or lysine mutant Vpx proteins or GFP as a control. Virus infection
was gauged from quantitation of late viral cDNAs and 2-LTR cDNAs 48 h post infection (error bars are s.d. of 3 replicate measures of a single DNA
sample). (C) Packaging of wild type and non-ubiquitylated Vpx proteins in virus particles (upper panel). The presence of Vpx in gradient purified
virions was determined by Western blotting with an HA antibody (lower panel).
doi:10.1371/journal.ppat.1000057.g003
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modest yet significant effect on SIV infection and ALLN and
proteasome inhibitor 1 (Prot.1) markedly impaired SIV infection
of macrophages (Figure 4). In contrast, neither ALLN nor
proteasome inhibitor 1 affected SIV infection of COS cells
(Figure 4). Identical results were obtained for HIV-2 in that the
proteasome inhibitors compromised macrophage infection but not
COS cell infection (Figure S2). In contrast, macrophage infection
by HIV-1 (which does not contain Vpx) was not compromised by
the proteasome inhibitors (Figure 4, right panel). Since
proteasome disruption only impacted virus infection of cells in
which Vpx was required for infection, this argued that proteasome
inhibition specifically impaired Vpx function rather than impact-
ing virus infection through off-target effects. The proteasome
inhibitor lactacystin exerted a more modest but significant effect
on SIV and HIV-2 infection of macrophages when compared to
the other proteasome inhibitors. However, we were unable to test
lactacystin in primary macrophages at higher concentrations
because of toxicity. Similar toxic effects of proteasome inhibitors in
primary dendritic cells have also limited complete suppression of
proteasome function using such inhibitors [17]. Collectively, these
experiments indicate the presence of a potent antiviral restriction
in macrophages that is counteracted by the Vpx protein and that
the proteasome/ubiquitin system is required for the ability of Vpx
to counteract this restriction.
The macrophage restriction is active against HIV-1
We next evaluated whether the antiviral restriction which
antagonized HIV-2/SIVSM infection of macrophages was active
against HIV-1. We first examined whether the Vpx protein, when
packaged in trans within HIV-1 virions, enhanced virus infectivity
for primary macrophages. While Vpx had no significant effect on
the infectivity of wild type HIV-1, the infectivity of HIV-1D Vpr
for macrophages was profoundly enhanced by Vpx but not by
HIV-1 Vpr (Figure 5A, lower panel). The infectivity enhance-
ment was also apparent in macrophages infected with an HIV-1
variant expressing green fluorescent protein (GFP) (Figure 5B).
Thus, while HIV-1 was infectious for macrophages, its ability to
infect these cells was markedly enhanced in the presence of Vpx.
Vpx had no effect on the infectivity of wild type or DVpr HIV-1
for COS cells (Figure 5A, upper panel). A possible explanation
for the ability of Vpx to compliment HIV-1 DVpr but not wild-
type HIV-1 is that Vpx and HIV-1 Vpr proteins compete for
packaging within HIV-1 virions. An alternative possibility was that
these proteins do not compete for packaging into virions but
compete for interaction with the restriction after infection has
occurred. Western blotting analysis revealed that both wild type
and lysine mutant (VpxM4) Vpx proteins were packaged into wild
type and Vpr deleted HIV-1 virions (Figure 5C). This suggested
that HIV-1 Vpr competed with Vpx in the target cell following
infection and this competition precluded the ability of Vpx to
activate the restriction. A prediction of this is that delivery of Vpx
to this target cell prior to HIV-1 infection should be sufficient to
inactivate the restriction and subsequently enhance macrophage
infection by both wild type and Vpr deleted HIV-1. To evaluate
this, we bypassed the requirement for Vpx packaging by directly
introducing Vpx into the target cell by SIVWT infection. The
susceptibility of those cells to infection by wild type or Vpr-deleted
HIV-1 variants was then examined. In this case, the infectivity of
both wild type and vpr deleted HIV-1 variants for macrophages
was enhanced when Vpx was first introduced into the cell by
SIVWT infection (Figure 5D). In contrast, prior infection with a
SIVD Vpx variant did not enhance subsequent HIV-1 infection of
macrophages (Figure 5D). Therefore, in the absence of
competition by packaged Vpr, Vpx greatly enhanced HIV-1
infectivity for macrophages. We next evaluated whether the ability
of Vpx to enhance HIV-1 infectivity depended upon its
ubiquitylation. As was the case for SIV, a Vpx mutant lacking
ubiquitylation sites (VpxM4) did not enhance HIV-1 infectivity
when packaged within HIV-1D Vpr virions (Figure 6A). This was
also apparent in infections using indicator viruses (Figure 6B). In
this case, the ability of Vpx to enhance the infectivity of a Vpr
deleted HIV-1 variant expressing GFP was compromised by the
M4 mutation. In addition, the ability of Vpx to enhance HIV-1
infectivity required proteasome function in that Vpx failed to
enhance permissiveness of macrophages to HIV-1 infection in
macrophages in which proteasome function was disrupted by
ALLN or proteasome inhibitor 1 (Figure 6C).
Vpx function requires damaged DNA binding protein 1
(DDB1)
Recent studies have demonstrated that the ability of HIV-1 Vpr
to induce cell cycle arrest requires the E3 ubiquitin ligase complex
scaffolding factor, damaged DNA binding protein 1 (DDB1) [26–
30]. Therefore, we examined whether the ability of Vpx to
Figure 4. Differential impact of proteasome inhibition on SIVWT and HIV-1 infection of macrophages. Effects of 3 different proteasome
inhibitors on SIV infection of macrophages and COS cells and HIV-1 infection of macrophages are indicated. Viral infection (2-LTR cDNA) was gauged
at 24 and 48 h post infection (error bars and s.d. of 3 replicate measures of a single DNA sample).
doi:10.1371/journal.ppat.1000057.g004
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counteract the macrophage restriction to SIV and HIV-1 infection
was DDB1-dependent. In 293T cells, endogenous DDB1 associ-
ated with a wild-type SIV Vpx protein but not with a SIV Vpx
mutant lacking lysine residues (VpxM4) (Figure 7A). A specific
association of SIV Vpx with DDB1 was apparent in coimmuno-
precipitation experiment with either FLAG-tagged Vpx or with
HA-tagged Vpx proteins (Figure 7A). If DDB1 is a functional
Vpx interactor, we would predict that DDB1 silencing would only
impact SIV infection of macrophages in which the restriction was
expressed but not in COS cells which lack the restriction. In
addition, HIV-1 Vpr did not antagonize a macrophage restriction.
The activity of the restriction in HIV-1 was only revealed by the
ability of Vpx to enhance HIV-1 infection of macrophages.
Therefore, a prediction is that DDB1 silencing should not inhibit
infection of macrophages by HIV-1. DDB1 specific siRNAs
efficiently reduced DDB1 expression in COS cells and in
macrophages (Figure 7B, left panels). While DDB1 silencing
had no significant effect on SIV infection of COS cells (p.0.05),
SIV infection was significantly impaired (p,0.005) in DDB1-
depleted macrophages (Figure 7C, upper right panel). In
contrast, macrophage infection by HIV-1 was not affected by
DDB1 silencing (Figure 7C, lower right panel). We also used
an independent strategy to deplete DDB1 in macrophages to
assess its role in virus infection. Similar to the results obtained with
siRNA mediated DDB1 depletion, depletion of DDB1 using
DDB1-specific shRNAs also specifically impaired the susceptibility
of primary macrophages to SIV infection but not HIV-1 infection
(Figure S3). Therefore, DDB1 appears to be a specific Vpx
cofactor in primary macrophages.
We next examined whether DDB1 was required for the ability
of Vpx to counteract the restriction to HIV-1 infection. Since Vpx,
when packaged in HIV-1 virions, enhanced macrophage infection,
Figure 5. HIV-1 is sensitive to the macrophage restriction and SIV Vpx but not HIV-1 Vpr antagonizes the restriction. (A) HIV-1 Vpr
and SIV Vpx proteins were packaged in HIV-1WT or HIV-1Dvpr viruses by cotransfection (for controls, viruses were transfected with an empty vector or a
GFP-expressing vector). The infectivity of those viruses for COS (upper panel) and macrophages (lower panel) was then determined from levels of
viral cDNA (2-LTR circle) at 24 and 48 h post infection. (B) Infection of macrophages with GFP-expressing HIV-1DVpr variants in which Vpx was (+) or
was not (2) packaged. GFP positive macrophages (representative fields) were visualized 48 h post infection (C) Packaging of Vpx proteins in wild
type and Vpr deleted HIV-1 (D) Vpx delivered to macrophages by SIVWT infection enhances the permissivity to HIV-1WT and HIV-1Dvpr infection.
Macrophages were first infected (1u infection) with wild type or DVpx SIV variants, left uninfected (none) or treated with AZT. After 8 h, these cells
were super-infected (2u infection) with WT or DVpr HIV-1 variants and HIV-1 infection (2-LTR cDNA synthesis) was determined 24 and 48 h later (error
bars are s.d. of 3 replicate PCRs of a single DNA sample).
doi:10.1371/journal.ppat.1000057.g005
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we examined whether Vpx enhanced HIV-1 infection in DDB1
depleted macrophages. While packaging of Vpx in HIV-1 particles
markedly increased infectivity for macrophages transfected with a
scrambled siRNA (Figure 8A) silencing of DDB1 in macrophages
significantly reduced (p,0.002) the ability of Vpx to enhance
HIV-1 infection (Figure 8A). However, DDB1 silencing had no
significant effect (p.0.05) on the infectivity of HIV-1 which had
not packaged Vpx (Figure 8A). Since SIV Vpx but not SIV Vpr
was essential for macrophage infection (Figure 1A), we examined
whether fusion of DDB1 to SIV Vpr was sufficient to allow SIV
Vpr to counteract the macrophage restriction. Packaging of Vpr
alone into a Vpr and Vpx deleted SIV (SIVDXR) did not permit
macrophage infection. In contrast, there was a partial and
significant (p,0.005) restoration of infectivity when a Vpr-
DDB1 fusion was packaged relative to infectivity of virions in
which the DDB1 protein was not packaged (Figure 8C).
Although ubiquitylation was necessary for the ability of Vpx to
counteract the restriction to HIV-1 and SIV infection of
macrophages, DDB1 protein was not required for Vpx ubiquityla-
tion (Figure 8C). Mono and poly ubiquitylated forms of Vpx were
evident and apparently increased in cells in which DDB1
expression was reduced by RNA interference (Figure 8C).
Collectively, these results suggest that DDB1 is required for the
ability of Vpx to antagonize a restriction to infect macrophages by
HIV-1 and SIV but that DDB1 is not required for Vpx
ubiquitylation.
Discussion
Our study suggests that the function of Vpx is to antagonize an
antiviral restriction in macrophages. Vpx exhibits similarities with
the Vif protein of primate lentiviruses in that inactivation of the
restriction required the proteasome/ubiquitin system. A role for
the proteasome/ubiquitin system is provided by our demonstra-
tion that ubiquitylation mutants of Vpx are functionally attenuated
and treatment of macrophages with proteasome disrupting agents
specifically reduces their susceptibility to SIV infection but not
HIV-1 infection. The inhibitory effect of proteasome inhibitors on
SIV infection of primary macrophages as reported in our study
appears to be at odds with studies demonstrating that HIV-1
Figure 6. Ubiquitylation is required for enhancement of HIV-1 infectivity in macrophages. (A) Infectivity of HIV-1 variants packaging wild
type or lysine-mutant Vpx proteins. Wild type HIV-1 Vpr, SIV Vpx or lysine mutant Vpx (VpxM4) proteins were packaged in HIV-1Dvpr and infectivity of
those viruses was assessed on macrophages. Viral cDNA synthesis was evaluated 24 and 48 h post-infection. (B) Infection of macrophages with HIV-
1DVpr GFP variants packaging wild type or mutant Vpx proteins. Cells were visualized 48 h post-infection. (C) The ability of Vpx to enhance
permissivity of macrophages to HIV-1 infection requires a functional proteasome. Macrophages were treated with the proteasome inhibitors ALLN or
proteasome inhibitor 1 (Prot. 1) or with DMSO as a control. Those cells were then infected with HIV-1Dvpr variants which had packaged wild type or
lysine mutant Vpx proteins. The level of viral infection (2-LTR cDNA) was determined 24 h post-infection by PCR (error bars are s.d. of 3 replicate PCRs
of a single DNA sample.)
doi:10.1371/journal.ppat.1000057.g006
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Figure 7. Inactivation of the macrophage restriction to SIV by Vpx requires DDB1. (A) Association of SIV Vpx with endogenous DDB1.
Association of DDB1 with wild-type Vpx (VpxWT) and non-ubiquitylated Vpx (VpxM4) was evaluated in 293T cells expressing FLAG-tagged Vpx (left
panels) or HA-tagged Vpx (right panels) or IRES-GFP as a control. FLAG and HA immunoprecipitates were immunoblotted with DDB1 or FLAG and HA
antibodies (upper panels). Levels of endogenous DDB1 and expressed Vpx in cell lysates were confirmed by Western blotting with a DDB1 antibody
and with FLAG/HA antibodies respectively (lower panels). (B) Efficiency of siRNA-mediated silencing of DDB1 expression in COS cells and in
macrophages was evaluated by Western blotting with DDB1 antibody at the indicated intervals post siRNA-transfection (ScrI-scrambled siRNA
control). (C) Impact of DDB1 silencing on SIV and HIV-1 infection of COS cells and macrophages. SIV and HIV-1 infection was gauged from the
quantity of viral cDNA (2-LTR) at 24, 48 and 72 h post infection (+, p.0.05; *, p,0.005) (error bars are s.d. of replicate PCRs of a single DNA sample).
doi:10.1371/journal.ppat.1000057.g007
Figure 8. DDB1 is required for the ability of Vpx to counteract the restriction to macrophage infection by HIV-1. (A) SIV Vpx (or GFP as
a control) was packaged into HIV-1DVpr virions as described in Figure 5. Infectivity of those viruses for DDB1-depleted macrophages (DDB1 siRNA) or
control macrophages (ScrI siRNA) were evaluated from levels of viral cDNA 24 h later (+, p.0.2; *, p,0.002). (B) DDB1 packaging partially substitutes
for Vpx. A Vpx/Vpr deletion mutant of SIV (SIVDXR) was co-transfected with vectors expressing SIV Vpr, SIV Vpx, DDB1 or a Vpr-DDB1 fusion. Infectivity
of the resulting viruses for macrophages was evaluated from levels of SIV cDNA at 24 and 48 h post infection (*, p,0.005). (C) Impact of DDB1
silencing on Vpx ubiquitylation. 293T cells were cotransfected with DDB1 or scrambled siRNAs and with HIS-ubiquitin and HA-Vpx or IRES-GFP
expression plasmids as outlined in Figure 3. Ubiquitin-conjugated proteins were nickel purified and immunoblotted for Vpx (HA). Cell lysates were
directly blotted for Vpx and DDB1 proteins (lower two panels).
doi:10.1371/journal.ppat.1000057.g008
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infection of cell lines is enhanced in the presence of proteasome
inhibitors [31–35]. The majority of these studies have involved cell
lines and one of these studies [31] has suggested that proteasome
inhibitors enhance HIV-1 infection by inducing G2/M cell cycle
arrest thereby imparting a cellular environment that is more
permissive to infection. Our study used primary macrophages and
since these cells are terminally differentiated and nondividing,
enhancing effects of proteasome inhibitors due to cell cycle arrest
would not be manifest. A comparison of our study with the study
Goujon et. al. [17] demonstrates that Vpx is essential for infection
of macrophage (our study) and of dendritic cells [17]. However,
there are some differences in the results obtained with Vpx mutant
viruses in these two systems. In the study of Goujon et al. [17], the
proteasome inhibitor MG132 marginally (1–2 fold) increased viral
DNA accumulation in dendritic cells in the presence of Vpx
whereas in our study, proteasome inhibitors markedly inhibited
infection of macrophages by SIV but not HIV-1. Since Goujon et
al. [17] reported that primary human dendritic cells were highly
sensitive to the toxic effects of MG132, it is possible that
differences in treatment conditions that can be employed in
macrophages versus dendritic cells could account for these
differences. The study of Goujon et al. [17] also showed an
enhancement of SIV infection in the absence of Vpx. We did not
examine the effects of proteasome inhibitors on a Vpx-deleted
virus in macrophages because this variant was essentially dead in
these cells.
Our study implicates DDB1 as a cellular cofactor of Vpx which
is necessary for the ability of Vpx to counteract the macrophage
restriction. This is supported by several independent experiments.
DDB1 silencing in macrophages specifically impaired their
susceptibility to infection by SIV and, in addition, impaired the
ability of Vpx to enhance infectivity of macrophages by HIV-1. It
is not possible to conclude at present whether DDB1 association
accounts, in totality, for the biological activity of Vpx. DDB1
silencing led to a 5–10 fold reduction in SIV infectivity of
macrophages whereas there was a 100 fold infectivity defect
imparted by deletion of Vpx. However, RNA silencing failed to
completely deplete DDB1 from primary macrophages and it is
possible that residual DDB1 allowed some retention of Vpx
activity in these macrophages. We also present evidence that
DDB1 binds to ubiquitylated Vpx and that lysine mutants of Vpx
which are inefficiently ubiquitylated exhibit reduced DDB1
binding and are impaired in their ability to support SIV infection
of macrophages. Using a Vpx mutant lacking lysine residues, we
present evidence that Vpx ubiquitylation is important for
association with DDB1 and to counteract the macrophage
restriction. Although we attribute loss of Vpx function to lack of
ubiquitylation and loss of DDB1 binding, we cannot rule out the
possibility that loss of function of the mutant protein was due to
indirect effects of the mutations on protein structure. However, at
the very least, the Vpx lysine mutant is packaged within virions
which suggests that it is competent for interaction with the p6
domain of the Gag polyprotein. As with DDB1 silencing, the
reduction in Vpx function imparted by mutation of all four lysines
in Vpx caused a no more than a 10 fold defect in Vpx function (for
example, see Figure 3B; Figure 6A,B). Therefore, ubiquitylation
and DDB1 association may not fully account for the biological
activity of Vpx in macrophages. However, polyubiquitylated forms
of Vpx were still evident in cells transfected with a Vpx mutant
lacking all lysine residues (Figure 3A). This suggests some degree
of Vpx ubiquitination on nonlysine residues [24,25]. Identification
and mutagenesis of all ubiquitination residues on Vpx will be
required before the degree to which Vpx activity depends upon
ubiquitination can fully be assessed. Our study also suggests that
DDB1 is not required for Vpx ubiquitylation but that Vpx
ubiquitylation is necessary for association with DDB1. Therefore,
the loss of function observed with the Vpx lysine mutant is likely to
reflect a loss in DDB1 binding. Although SIV Vpr did not
counteract the macrophage restriction, fusing it to DDB1 partially
conferred this ability. This suggests that the function of Vpx may
be to tether DDB1 to the reverse transcription complex upon
which the restriction acts. Our study also indicates that DDB1 is
required for the ability of Vpx to counter the macrophage
restriction to HIV-1 infection. HIV-1 Vpr did not exhibit the
ability to counter the macrophage restriction. For this reason,
silencing of DDB1 did not impair susceptibility of macrophages to
HIV-1 infection. However, the fact that the restriction was active
against HIV-1 was revealed by the demonstration that Vpx greatly
increased the permissivity of macrophages to HIV-1 infection. In
this situation, silencing of DDB1 inhibited the ability of Vpx to
enhance macrophage infection by HIV-1. Although Vpx is a
virion protein, we do not know if DDB1 itself is packaged within
virions. However, since silencing of DDB1 in the target cell
inhibited SIV infection, this suggests that Vpx usurps DDB1 after
infection of the target cell and likely, within the context of the
reverse transcription complex.
Our study also reveals a paradox with regards to the functional
consequences of HIV-1 Vpr and HIV-2/SIV Vpx interaction with
DDB1. DDB1 mediates the cell cycle arrest property of HIV-1
Vpr. DDB1 was also necessary for the ability of SIV Vpx to
counteract the macrophage restriction. However, SIV Vpx,
although able to interact with DDB1, does not induce cell cycle
arrest. Furthermore, the ability of HIV-1 Vpr to interact with
DDB1 does not appear sufficient to confer upon HIV-1 Vpr the
ability to efficiently counteract the macrophage restriction.
Therefore, there are likely to be different biological outcomes
that are dictated by the nature of the interactions that HIV-1 Vpr
and SIV Vpx forge with DDB1 and its associated E3 ubiquitin
ligase complex components. Further insight into the mechanisms
employed by HIV-1 Vpr and HIV-2/SIVSM Vpx to enhance
macrophage infection may be revealed once the macrophage
restriction itself is identified.
Materials and Methods
Proviral DNAs, virus stocks and infections
The infectious molecular clone SIVSM PBj1.9 was used for the
majority of experiments in this study. This clone, which is
representative of the HIV-2/SIVSM group of viruses, was derived
from short-term peripheral blood mononuclear cell (PBMC)
cultures. Unlike many other HIV-2 and SIVSM clones, PBj1.9
has a complete set of uninterrupted accessory genes and replicates
efficiently in macrophages and represents a physiologically
relevant virus strain. Mutations which abrogated the translation
of Vpx and Vpr genes are as described previously [4]. HIV-GFP (a
gift of Paul Clapham, University of Massachusetts Medical School)
contains an EGFP gene inserted between the envelope stop codon
and nef within the HIV-1NL4-3 backbone. GFP expressing variants
of wild type and DVpx SIV contain an EGFP gene inserted
between Bst 1107I sites within the viral envelope gene (as
schematized on Figure 2). Wild type and DVpr HIV-1 variants
were studied in the context of HIV-1NL4-3. For the generation of
viral stocks, 293T cells were transfected with proviral DNAs
(25 mg) using a modified calcium phosphate/DNA precipitation
method (Stratagene). Viruses were pseudotyped with VSV
envelope glycoproteins by cotransfection of proviral DNAs with
a plasmid expressing the VSV envelope glycoprotein. For
encapsidation of wild type and mutant Vpx and Vpr proteins,
Lentiviral Vpx Subverts a Macrophage Restriction
PLoS Pathogens | www.plospathogens.org 9 May 2008 | Volume 4 | Issue 5 | e1000057
293T cells were cotransfected with proviral DNAs and plasmids
expressing Vpx and Vpr proteins. The DNA ratio for pVSV-G,
proviral clones and pIRES2-EGFP-Vpx was 1:14:1. For encapsi-
dation of Vpr-DDB1 fusion proteins, 293T cells were co-
transfected with an SIV deltaVpx/deltaVpr proviral clone,
pIRES2-EGFP Vpr-fDDB1 and pVSV-G. The DNA ratio for
pVSV-G, proviral clone and DDB1 expression plasmids was
1:14:1. HIV-1 and SIV stocks were normalized on the basis of
reverse transcriptase activity. Viral infection efficiency was gauged
from synthesis of viral cDNA products at early intervals (24 and
48 h) post-infection. PCR conditions for amplification of SIVSM
and HIV-1 2-LTR cDNAs are as described previously [4,36].
cDNA copy numbers were expressed on a per cell basis after
quantitation of genomic DNA copy numbers using PCR and
primers to the CCR5 gene [36]. Macrophages were initially
infected with VSV-pseudotyped SIV variants harboring intact or
defective Vpx genes. Viruses used in the initial infection
additionally lacked an intact envelope open reading frame.
Macrophages were then super-infected with SIV variants which
harbored intact envelope genes. As a consequence, cDNA
products generated specifically by the super-infecting virus could
be identified. SIV cDNA products were amplified in two rounds of
PCR with JumpStartTM RedaccuTag
TM DNA polymerase (Sigma).
First round products were amplified using forward (taacaggaa-
caccagcaccaaca) and reverse (catctgctttccctgacaa) primers. Second-
round products were amplified using forward (taacaggaacaccag-
caccaaca) and reverse (aagcataacctggcggtgcaca) primers.
Gradient purification of virions
Supernatants from 293T cells transfected with infectious
molecular clones were cleared of cellular debris by low-speed
centrifugation (1500 g, 10 min) and then filtered (0.45 mm).
Virions in clarified supernatants were harvested (10,000 g, 2 h)
and resuspended in serum-free medium (500 ml). Concentrated
virions were applied to a 15–60% w/v continuous sucrose gradient
and virions were resolved at 200,000 g for 16 h. Gradient fractions
(0.5 ml) were collected and virus levels in each fraction were
measured by reverse transcriptase activity. Virus particles in
individual gradients were pelleted and resuspended in sample
buffer and the presence of encapsidated Vpx proteins was
examined by Western blotting with an aHA antibody.
Macrophages and cell lines
Peripheral blood monocytes were obtained by elutriation and
counter current centrifugation and maintained 2 days in DMEM
containing 10% human serum and monocyte colony stimulating
factor (MCSF) (RD Systems) and for a further 5 days in medium
lacking MCSF prior to use in experiment. 293T, Hela and COS
cells were maintained in DMEM containing 10% FBS.
Proteasome inhibition
Macrophages or COS cells (86105) in 24 well plates were directly
infected with VSV-G-pseudotyped viruses (16106 cpm RT/ml or 1
ug p24/ml) in the presence of proteasome inhibitors including
Lactacystine (10 uM), ALLN (50 uM) and Proteasome inhibitor 1 (50
uM). After 3–5 h, supernatant was removed and replaced with fresh
medium containing proteasome inhibitors. After 24 and 48 h post-
infection total DNA was isolated using DNAzol reagent (Invitrogen)
and analyzed by real-time PCR assay for 2LTR circles.
Cell staining
For FACS analyis, COS cells and human macrophages were
stained with 3.5 mM CellTracker Green CMFDA (5-chloro-
methylfluorescein diacetate) and 24 mM CellTracker Blue CMAC
(7-amino-4-chloromethylcoumarin), respectively. For fluorescence
microscopy, COS cells and macrophages were stained with
2.5 mM DiO (3,39-dioctadecyloxacarbo cyanine perchlorate) and
12 mM DiI (1,19-dioctadecyl-3,3,39,39-tetramethylindocarbocya-
nine perchlorate) respectively, according to manufacturer’s
instructions (Molecular Probes).
Cell fusion
Generation of macrophage homokaryons was achieved by
polyethylene glycol (PEG). Briefly, labeled cells, 156106 each
group, were mixed and centrifuged at 250 g. 50% PEG-1450 was
added dropwise to the pellet and cells incubated for 2 min at 37uC
with gentle mixing. 1 ml PBS was then added dropwise to the cells
over 1 min, followed by 3 ml of 2% FBS/PBS over another
2 minutes. Cells were washed 3 times with 2% FBS/PBS and
plated in a 100 mm culture dish (16107 cells/dish). COS-
macrophage and COS-COS cell fusion was achieved using
paramyxovirus hemagglutinin-neuraminidase (HN) protein and
fusion (F) protein. Briefly, COS cells were transfected with
pCAGGS-HN and pCAGGS-F expression vectors encoding HN
and F proteins of Newcastle disease virus (gift of Prof. T. Morrison)
[37]. Sixteen to twenty hours post-transfection, COS cells were
stained, mixed with stained macrophages (ratio 1:1.5) and plated
in 100 mm dishes. COS homokaryons were generated at 1:1 ratio.
After overnight incubation, cells were infected with either SIVWT
or SIVDVpx for 24 h. Cell sorting was performed with a FACSAria
flow cytometer using the FACSDiva software (Becton Dickinson).
Double-stained cells were sorted. Total DNA was isolated using
DNeasy Blood and Tissue Kit (Quiagen) and analyzed by real-
time PCR assay for 2LTR circles.
Plasmids
The SIVsm Vpx and HIV-1 Vpr genes were amplified from
PBj1.9 and NL4.3 proviral clones respectively, and inserted into
a pIRES2-EGFP vector (BD) either with or without a N-terminal
minimum HA epitope. The upstream primer for each PCR
product provided a Kozak sequence. The Vpx lysine mutants
(K68,77,84,85R) were generated by Quikchange XL site-
directed mutagenesis (Stratagene). The DDB1 gene was
amplified and subcloned from pBj-hp125 (ATCC, MBA-126)
and inserted into pIRES2-EGFP as an in frame fusion with the
C-terminal of SIV Vpr. A Flag epitope was added to the N-
terminal of DDB1 as flanking sequences between Vpr and
DDB1. As a control, a N-terminal Flag tagged DDB1 was
inserted into pIRES2-EGFP.
Analysis of Vpx ubiquitylation
293T cells were co-transfected with HA-Vpx, HA-Vpx lysine
mutants or a pIRES2-EGFP empty vector and pRGB4-6His-myc-
Ubiquitin at a 1:4 ratio using lipofectamine 2000 (Invitrogen).
Non-6His tagged Ubiquitin was included as a control for Ni-NTA
pull-down. 36 h after transfection, the 6His-ubiquitin conjugated
proteins were purified using Ni-NTA Magnetic Agarose beads
(Qiagen) under native conditions [38]. Briefly, cells were lysed in
detergent buffer (10 mM Tris-Hcl pH7.5, 150 mM NaCl,1%
Triton X-100 and protease inhibitor cocktail) and clarified by
centrifugation at 14,000 rpm for 15 min. The cell lysates were
incubated with Ni-NTA beads overnight at 4uC in detergent
buffer with 300 mM NaCl, 20 mM imidazole and 5 mM MG132.
The beads were washed in lysis buffer and attached proteins were
eluted in elution buffer (50 mM NaH2PO4, 375 mM NaCl, 1%
Triton, 250 mM imidazole pH 8.0).
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Immunoblotting
Virus pellets were lysed in RIPA buffer (50 mM Tris-Hcl pH
7.5, 150 mM NaCl, 1% NP-40, 0.5% NaDoc, 0.1% SDS and
protease inhibitor cocktail) lysates of transfected cells or gradient
purified virions were boiled in sample buffer, resolved by SDS/
PAGE and Western blotted with the following antibodies: HA-
Vpx (HA, 16B12, Covance), myc-Ubiquitin (a-ubiquitin, P4G7,
Covance; a-Myc 9E10, Sigma), Capsid (polyclonal, ABI), c-
tubulin (GTU-88, Sigma), Flag-Vpx (M2, F3165, Sigma), DDB1
(Goat polyclonal antibody PC718,Calbiochem).
RNA interference of DDB1
The siRNA sequences for DDB1 silencing in macrophages,
COS-1 or 293T cells were
siRNA1: GCAAGGACCTGCTGTTTAT
siRNA2: GCATGCCAGCATTGACTTA
siRNA3: CCTGCATCCTGGAGTATAA
The Scrambled control siRNA sequence was
CAGTCGCGTTTGCGACTGG
Macrophages or COS-1 cells were transfected twice with
60 pmol each siRNA using lipofectamine 2000. 24 h after siRNA
transfection, cells were infected with RT-normalized virus as
indicated. The DDB1 protein knockdown levels were examined at
the same time point as cDNA analysis.
For shRNA-mediated DDB1 silencing, macrophages are
infected with a TRIP lentiviral vector [39] containing or lacking
DDB1 hairpin sequences. 48 h after transduction with shRNA
lentivirus vectors, macrophages were infected with VSV-g-
pseudotyped SIV or HIV-1 and levels of viral cDNA synthesis
was assessed after additional 48 h (96 h post lentivirus vector
transduction).
Vpx-DDB1 co-immunoprecipitation
293T cells were transfected with Flag-Vpx, Flag-Vpx lysine
mutant (VpxM4) or pIRES2-EGFP vector. 36 h after transfection,
cells were harvested and lysed in Co-IP lysis buffer (100 mM
NaCl, 50 mM Tris-Hcl pH 7.5, 5 mM MgCl2, 0.5% NP-40,
protease inhibitor cocktail) and incubated with Protein A and
Protein G beads (Invitrogen) conjugated anti-Flag M2 antibody
overnight at 4uC. The beads were washed 4 times in a more
stringent wash buffer (400 mM NaCl, 50 mM Tris-Hcl pH 7.5,
5 mM MgCl2, 0.5% NP-40, protease inhibitor cocktail). And
bound proteins were boiled and eluted in 26 Laemmli’s SDS-
sample buffer.
Statistical Analysis
Where indicated, data was analyzed using an unpaired Students
t test. p values of 0.05 or lower were considered significant.
Statistical analysis was performed using Graph Pad Prizm 5
software.
Supporting Information
Figure S1 Susceptibility of macrophages to infection by wild
type and Vpx-deleted SIVSM variants. Virus infection was gauged
from the levels of late cDNA and 2-LTR cDNA products of
reverse transcription at 24 and 48 h post infection.
Found at: doi:10.1371/journal.ppat.1000057.s001 (0.09 MB TIF)
Figure S2 Differential impact of proteasome inhibition on HIV-
2WT infection of macrophage and COS cells. Effects of three
different proteasome inhibitors on HIV-2 infection are indicated.
Viral infection (2-LTR cDNA) was gauged 24 and 48 h post
infection (error bars are s.d. of 3 replicate measures of a single
sample).
Found at: doi:10.1371/journal.ppat.1000057.s002 (0.12 MB TIF)
Figure S3 Differential impact of shRNA-mediated DDB1
silencing on infection of primary macrophages by SIV and HIV-
1. (A) DDB1 expression in primary macrophages at 72 and
96 hours post infection with a lentivirus vector expressing a DDB1
shRNA. Control cells were infected with a non shRNA expressing
lentivirus vector. (B) SIV cDNA and HIV-1 cDNA levels in SIV
and HIV-1 infected macrophages 96 h after transduction with
lentivirus vectors expressing a DDB1 shRNA or 96 h after
transduction with a vector control. Infections done in the presence
of AZT were used to assess the level of carry over viral DNA
contamination.
Found at: doi:10.1371/journal.ppat.1000057.s003 (0.23 MB TIF)
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